anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE: To impart max. absorbance in a UV wavelength region to an oil dispersion by compounding oil, titanium dioxide particles having an average size of 0.01 to 0.15 μm and an org. dispersant of particles, thereby preparing the oil dispersion of &gt;=40 wt.% in solid weight. CONSTITUTION: Titanium dioxide particles having the average size of 0.01 to 0.15 μm are pulverized in the presence of a granular pulverizing media in the oil and in the presence of the org. dispersant for titanium dioxide in the oil, by which the oil dispersion contg. &gt;=40 wt.% titanium dioxide is produced. The resulted oil dispersion has the max. absorbance of at least 401/g/cm in the UV wavelength range. The pulverization is preferably executed at a speed of 3500 to 7000 revolutions/min and the pulverizing media are adequately sand, glass beads or the like. The oil includes vegetable oils, fatty acid esters, aliphat. alcohols, satd. fatty acid diesters or the like.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a hair restoring apparatus to utilize negative ions for the hair.  &lt;P&gt;SOLUTION: The negative ion from a coral utilizing negative ion generating means 10 is sent to a negative ion sprinkling means 20 comprised of a duct 21 and a negative ion emitting hair capsule 22. The negative ion generating means 10 produces the alkali ion water by making a coral ceramic particles aggregate 11a stored in a removable water container 12a react on the water with an ultrasonic vibration of an ultrasonic generator 13. The ultrasonic generator 13 gives the ultrasonic vibration also to the ion water and makes the ion water be a negative ion fog drip A. A fan F spirally ventilates the negative ion fog drip A through a negative ion fog drip passage 14b which is formed of a cylinder 14c disposed in a negative ion fog drip storing chamber 14a. A water conduit 15 exists between the removable water container 12 and the ultrasonic generator 13, and the ion water is poured into a storing section 14d at the bottom of the negative ion fog drip storing chamber 14a wherein the ultrasonic generator 13 exists.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a functional substance which acts excellently as a foaming promoter, a skin detergent, a hair wash and/or a body odor adsorbent; a detergent composition containing the functional substance; and a body odor adsorption composition.  &lt;P&gt;SOLUTION: Micronized allophane having an average particle size of 0.01 to 100 μm increases a foaming promotion effect, promotes foaming and foam cutting in a short period of time, and strengthens durability of foam. Further, adsorption power to oily soil due to free fatty acid (particularly, unsaturated fatty acid), and secreted sebum and keratotic plug is increased; and the function as the skin detergent and the hair wash is significantly strengthened. Furthermore, the function as the body odor adsorbent is remarkably strengthened, and the body odor of old personss and a foot smell are powerfully adsorbed. Still furthermore, conformability to a human skin is significantly improved.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PCT No. PCT/ES96/00192 Sec. 371 Date Aug. 12, 1997 Sec. 102(e) Date Aug. 12, 1997 PCT Filed Oct. 11, 1996 PCT Pub. No. WO97/13754 PCT Pub. Date Apr. 17, 1997New polycyclic aminopyridine compounds which are acetylcholinesterase inhibitors, process for preparing them and their use. The polycyclic aminopyridine compounds correspond to the formula in which the various radicals have the meanings stated in the specification. The process for preparing these compounds is characterized in that ketones of general formula (II) are reacted with aminonitriles of general formula (III) and, if necessary, the compounds of formula (I) are alkylated, aralkylated or acylated, or alternatively the corresponding keto precursor is reduced. The compounds of the general formula (I) are especially suitable for the preparation of medicaments against memory disorders such as senile dementia or Alzheimer&#39;s disease.
PROBLEM TO BE SOLVED: To obtain a bathing agent having humectant effects, etc., on the impartment of a moist feeling or a smooth feeling to skin and capable of suppressing an increase in bloodstream due to bathing by formulating saccharides and amino acids in combination. SOLUTION: This bathing agent contains (A) saccharides and (B) amino acids. The ingredient A is soluble in water and, e.g. monosaccharides, oligosaccharides, dextrin and a mixture thereof are cited. Amino acids, amino acid salts and a mixture thereof are cited as the ingredient B. The total content of the ingredients A and B is preferably &gt;=50 wt.% and the formulating ratio of the ingredients A and B is preferably 1:(0.1-10) expressed in terms of weight ratio. A bathing agent containing sucrose as the ingredient A and a sodium salt of an acidic amino acid as the ingredient B without substantially containing inorganic salts is cited as the preferred bathing agent. Thereby, the occurrence of pruritus, etc., of skin due to the increase in bloodstream at the time of baking can be suppressed and bathing without anxiety can be afforded.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a dental prosthesis having adequate strength and high safety and excellent in affinity/contactness for oral mucous membrane.  &lt;P&gt;SOLUTION: The dental prosthesis consists mainly of a plastic material. A saponified product (EVOH) of an ethylene-vinyl ester copolymer is used as the plastic material. The EVOH is a resin having merits having good hydrophilicity and having good contactness with oral mucous membrane, because the EVOH is swollen by saliva in oral cavity and excellent in safety, because the EVOH has adequate hardness and does not discharge a component poisonous to human bodies even by heating or hydrolysis, etc. and excellent in moldability because of thermoplastic resin. The dental prosthesis is particularly used as a denture base or a mooring member for denture base.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The invention relates to stasis eliminating powder for treating soft tissue injury and cervical spondylosis. The stasis eliminating powder is prepared from the following raw material drugs in parts by weight: 1150 to 1350 parts of dandelion, 400 to 600 parts of rhubarb, 400 to 600 parts of myrrh, 400 to 600 parts of pseudo-ginseng, 400 to 600 parts of Chinese polyphaga, and 725 to 925 parts of geranium wilfordii. The invention also provides application of the stasis eliminating powder. The stasis eliminating powder has the advantages that: the stasis eliminating power is compatible with a principle of Chinese medicament &#39;monarch, minister, assistant and guide&#39;, and has the remarkable effects of dissipating blood stasis to promote menstruation, and alleviating pain and removing stagnation. The stasis eliminating powder is suitable for treating pains, swelling and inflammations caused by cervical spondylosis, osteoarthritis, lumbar muscle strain, lumbar disc herniation, rheumatoid arthritis, hyperosteogeny, gout and scapulohumeral periarthritis, and also can be used for treating symptoms of traumatic injuries, blood stasis, undispersed abdominal stasis and joint stasis. The stasis eliminating powder has less toxic and side effects and good curative effect, contains few medicaments and is suitable for long-term administration, and thus the stasis eliminating powder is a safe and effective medicament.
Glycan ingredient MF4 has increased immunological competence and anti-tumour functions, which is separated from sea-animal thick shell mussel. Its relative molecular weight is 113,000. It was analyzed and identified the physical properties and chemical structure through multiple spectra and methods, of which spectra are such as UV, IR, GC/MS,1HNMR, of which chemical methods are such as hydrolysis, acetylization, periodate oxidation, Smith degradation, methylation, sulfuric acid- carbazole reaction. Testing in vitro proves that MF4 promotes T,B lymph cells proliferation. Anti-tumour testing in vivo shows that small rat with subcutaneous inoculation is capable of inhibiting Lewis lung cancer and S-180 caruncle&#39;s growth, and has promotion functions for NK cell activity and lymph cell transfer of charged Lewis lung cance small rat. The thick shell mussel glycan MF4 is used to prepare new immonological strengthen pharmaceutics and anti-tumour drugs. And it&#39;s a new approach for developing Chinese sea biological sources.
An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and having potent in vitro chemotactic activity while inducing little or no in vitro chemokinesis in polymorphonuclear cells, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine has been isolated and its cDNA has been sequenced. The sequence predicts a cDNA of 74 amino acids in length and a molecular weight of 7,908. Diagnostic and therapeutic utilities are proposed, and testing procedures, materials in kit form, recombinant materials and procedures, and pharmaceutical compositions are likewise set forth. &lt;IMAGE&gt;
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an anticancer agent containing ferulae resina or volatile oil of the same as active ingredient.  &lt;P&gt;SOLUTION: This anticancer agent may be the preparations of injection, capsules, liquid droplets, tablets, granules powder or oral liquid. The volatile oil of the ferulae resina contains mainly α-pinene, 2-borneol, di-sec-butyl disulfide, sec-butyl trans-1-butenyl disulfide, sec-butyl-propenyl disulfide, dimethyl disulfide and dimethyl trisulfide. It is possible to extract the volatile oil of the ferulae resina by adopting a normal extraction method. The ferulae resina may be a factice resin derived from Sinkiang ferulae resina or Fukang ferulae resina, and also the factice resin derived from glia ferulae resina grass produced in the countries of Iran, Afghanistan, Sli Lanka, India, Iraq, Bengal, Pakistan, Kyrgyzstan, Kazakhstan, etc. The anticancer agent prepared from the ferulae resina or volatile oil of the ferulae resina can be applied for the treatment of patients suffered from various cancers.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
Provided are an antiacid nano particle oral deoxyribonucleic acid (DNA) anti-tumor vaccine with the potential of hydrogen (pH) sensitive characteristic and a preparation method. The DNA oral vaccine is nano particles formed by combining chitosan with alginic acid for surface finish and encoded tumor specific antigen Legumain protein DNA plasmids. The DNA oral vaccine is capable of being efficiently phagocytized by dendritic cells and macrophage in peyer&#39;s patches and expressing the encoded tumor antigen to activate immune damage of a host for tumor cells. The nano particles have small toxic and side effects and a strong antigen presentation role. Specifically, the DNA plasmids and chitosan are led to be in static negative crosslinking, and then, alginic acid is used for surface finish of chitosan nano particles. By means of immunofluorescent staining and flow cytometry, growth and transfer conditions of breast cancer of a mouse are estimated, immune response of the mouse is analyzed, and antigen presentation capability and anti-tumor effect of the antiacid nano particle oral DNA anti-tumor vaccine with the potential of pH sensitive characteristic are determined.
An  in vitro  microfluidic intestine on-chip is described herein that mimics the structure and at least one function of specific areas of the gastrointestinal system  in vivo . In particular, a multicellular, layered, microfluidic intestinal cell culture, which is some embodiments is derived from patient&#39;s enteroids-derived cells, is described comprising L cells, allowing for interactions between L cells and gastrointestinal epithelial cells, endothelial cells and immune cells. This  in vitro  microfluidic system can be used for modeling inflammatory gastrointestinal autoimmune tissue,  e.g. , diabetes, obesity, intestinal insufficiency and other inflammatory gastrointestinal disorders. These multicellular-layered microfluidic intestine on-chips further allow for comparisons between types of gastrointestinal tissues,  e.g. , small intestinal duodenum, small intestinal jejunum, small intestinal ileum, large intestinal colon, etc., and between disease states of gastrointestinal tissue, i.e. healthy, pre-disease and diseased areas. Additionally, these microfluidic gut-on-chips allow identification of cells and cellular derived factors driving disease states and drug testing for reducing inflammation.
There is provided a novel adenylate cyclase enzyme, the nucleotide sequence of which is set out in SEQ ID No. 1. The activity of the adenylate cyclase is uniquely regulated by calcineurin, a protein phosphatase. The calcineurin binding site has been identified at amino acids 503 to 610 of the novel adenylate cyclase. Regulation of the novel adenylate cyclase may be useful in treating certain disorders. Suitable regulators include agents which bind to the 503-610 amino acid site and include calcineurin, its activators, inhibitors and competitors and antibodies specific to that site. Specific disorders include neurological disorders such as Parkinsons&#39; disease, cardiovascular disorders such as angina pectoris and tumors, especially ovarian tumors.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition for a local application constituted by a distinctive transparent aqueous phase and a distinctive transparent oil phase.  &lt;P&gt;SOLUTION: This composition is provided by having the aqueous phase containing at least 40 wt. % 1 kind or in a plurality of polyols based on the total weight of the aqueous phase, and the oil phase containing at least 5 wt. % 1 kind or in a plurality of silicone oils based on the total weight of the oil phase, and having the amount of the polyols and the amount of the silicone oils so as to make the refractive indices of the two phases becoming substantially the same. The polyols are preferably selected from glycerol, dipropylene glycol or a mixture of the glycerol or dipropylene glycol with another polyol. The two distinctive phases are transparent, and while agitating the two transparent phases, the same transparent single phase is formed. The use of the composition in a cosmetic field, concretely for removing makeup, and cleansing and/or care of skin, lips and/or eyes is also provided.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To provide the titled substance consisting of edible fibers composed mainly of cellulose and hemicellulose produced by removing starches, proteins, etc., from shell of grains or beans. CONSTITUTION:Shells of grains or beans (e.g. corn, rice bran, wheat bran, barley bran, soybean, adzuki bean, peas, etc.) is subjected e.g. to enzymatic treatment (e.g. with a starch-decomposition enzyme such as alpha-amylase, a protein- decomposition enzyme such as protease, etc.) to remove starches, proteins and, if necessary, lipids, inorganic materials, etc., to obtain edible fibers (having an NDF value of &gt;=50%) composed mainly of cellulose and hemicellulose. The objective hepatic function-activation substance can be produced by using the edible fiber as a component. The substance is expected to have a remedying or preventive effect against various hepatic diseases and a normalizing action to hepatic function. It is absolutely free from toxicity and side effect. It can be produced at a low cost because of remarkably simplified production process.
A head bathing system for haircare. The system is composed of an outer cap having a head-receiving aperture, an inner, absorbent liquid-holding layer, and a flexible gathering for the cap at the aperture. The liquid-holding layer is impregnated with a cleansing solution. To clean a person&#39;s hair, the system is applied to the person&#39;s head, which is massaged through the cap to cause the cleansing solution to wet the person&#39;s hair. After sufficient cleaning, the system is removed from the person&#39;s head. Because of the nature of the liquid-holding layer, it reabsorbs much of the cleansing solution before the system is removed from the person&#39;s head.
Provided is the use of stilbene compounds in the preparation of anti-tumor medicaments, and related is the pharmaceutical field. The stilbene compounds of the present invention are compounds represented by formula I, or salts thereof, or stereoisomers thereof, or solvates thereof. In the present invention, it is discovered that stilbene compounds have a dual effect of enriching T lymphocytes CD8&lt;sup&gt;+&lt;/sup&gt; in solid tumors and targeting the destruction of the inner wall of tumor blood vessels. While killing tumor cells by cytotoxic T lymphocyte antigen CD8&lt;sup&gt;+&lt;/sup&gt;, the stilbenes cut off the blood supply to tumor tissues, cause rapid necrosis in solid tumors, greatly improve the killing effects on tumors, and inhibit tumor metastasis. Thereby, they can be used to prepare anti-tumor medicaments, and also used in combination with tumor immunotherapeutics to achieve synergistic anti-tumor effects. In addition, the stilbene compounds of the present invention can inhibit the growth of ocular surface blood vessels and be used in the preparation of medicaments for treating various eye diseases. The stilbene compounds of the present invention have good application prospects.
1. Technical Result Development of non-invasive method for imaging amyloid deposits with patients. 2. Essence The present invention provides a method of treating Alzheimer&#39;s disease using a compound of Formula (I) for inhibiting the aggregation of amyloid proteins and a method of imaging amyloid deposits. 3. Field of Application Medicine.
A combination of two drugs, from two different and previously unrelated categories, provides effective and long-lasting relief from neuropathic pain. Both drugs can be taken orally, in a convenient, painless, non-invasive manner that does not require injections. One drug in this combination is an α2 adrenergic agonist, exemplified by clonidine. The other drug in the combination is an adamantane derivative which has NMDA antagonist activity, such as memantine. Tests described herein demonstrate that when memantine is administered together with an α2 adrenergic agonist such as clonidine, these drugs mutually potentiate one another&#39;s neuropathic pain-relieving action, and provide potent and sustained neuropathic pain relief, even when each agent is administered at a low dosage that is below its threshold for causing adverse side effects. These results indicate that combining these two classes of drugs can provide safe and effective relief of neuropathic pain and possibly other types of chronic and/or intractable pain, without serious adverse side effects.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a nutrient composition for diabetes or blood sugar control, effective for the blood sugar control and complication prevention of a diabetes patient, enabling sufficient nutritional management, and having good flavor.  &lt;P&gt;SOLUTION: The nutrient composition for the diabetes or the blood sugar control contains glucides, proteins, lipids, dietary fiber, vitamins and minerals as nutrient components. The composition further contains catechins originated from tea, and L-arabinose and/or an extract of leaves of mulberry. The content of vitamin C per 100 kcal is 30-150 mg, and the content of vitamin E per 100 kcal is 3-10 mg. The ratio by weight of the catechins originated from the tea to the L-arabinose and/or the extract of the leaves of the mulberry is (1:2) to (1:5). The content of the dietary fiber is preferably 5-10 wt.% based on the whole solid components.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The Mycobacterium tuberculosis Ag38 gene, which encodes a highly immunogenic protein, was cloned into a retroviral vector in-frame with the leader and the transmembrane portion of the nerve growth factor receptor, and transduced into murine melanoma cell line B16-B78. Significant protection was observed in mice immunized with the transduced melanoma cells and subcutaneously challenged with parental melanoma cells since only 20% of mice developed tumors. Necroscopy of mice immunized with the transduced melanoma cells revealed dramatic inhibition of experimental metastases induced by intravenous (i.v.) inoculation of parental melanoma cells. Moreover vaccination with transduced cells significantly prolonged survival of mice challenged i.v. with parental melanoma cells. These data indicate that the presence of the mycobacterial 38-kDa protein greatly enhances immunological recognition of structures expressed by the parental melanoma cells. Comparison of Th1 and Th2 responses in mice immunized with parental melanoma cells versus mice receiving the transduced cells revealed a clear predominance of Th1 responses when the Ag38 protein was endogenously expressed. This novel transduction approach based on the 38kDa antigen may represent a promising immunotherapeutic strategy for the treatment of cancer patients. In addition, as vaccine the transduced cells may be used for inducing immunity to cancer. &lt;IMAGE&gt;
The application describes a method of treating pneumonia (e.g. COVID-19 pneumonia) in a patient comprising administering a weight-based intravenous dose of tocilizumab to the patient, wherein the weight-based dose is 8 mg/kg of tocilizumab. It also describes a method of treating pneumonia in a patient comprising administering an IL6 antagonist (e.g. an IL6 receptor antibody such as tocilizumab) to the patient in an amount effective to achieve a greater improvement in clinical outcome than standard of care (SOC) as measured on an ordinal scale of clinical status. Moreover, the application describes a method of treating pneumonia in a patient comprising: (a) administering a first weight-based 8 mg/kg intravenous dose of tocilizumab to the patient; and (b) further comprising administering a second weight-based 8 mg/kg intravenous dose of tocilizumab to the patient 8-12 hours after the first dose, wherein the patient experiences no improvement or &gt;one-category worsening on an ordinal scale of clinical status following the first dose. In addition, the application discloses a method of treating acute respiratory distress syndrome (ARDS) in a patient who does not have elevated IL6 level comprising administering an IL6 antagonist (e.g. an IL6 receptor antibody such as tocilizumab) to the patient.
PURPOSE:To facilitate molding without requiring operation for pH adjustment, etc., by adding water, a deflocculant and dispersant to a mixture composed of tricalcium phosphate, calcium carbonate and additive to prepare a slurry, putting the slurry into a gypsum mold and heating a slip cast molding piece, thereby obtaining the sintered body of apatite. CONSTITUTION:The water, the deflocculant and the dispersant is added to the mixture composed of the tricalcium phosphate, the calcium carbonate and the additive to prepare the slurry and the slurry is put into the gypsum mold and is slip cast molded, then the slip cast molding piece is heated, by which the sintered body of the apatite is obtd. The ratio of the tricalcium phosphate to the calcium carbonate is specified to 3:1 by molar ratio and the ratio of the water is specified to &lt;=50% by weight. The tricalcium phosphate is formed of a mixture composed of an alpha type and a beta type and the mixing ratio thereof is specified to the alpha type: beta type=0:1 to 3:1. Further, volatile camphor is used for the additive and the ratio thereof is specified to &gt;=4% by the weight ratio to the slip. The heating temp. of the molded piece is specified to 600 to 1200 deg.C.